MetLife Investment Management’s RxSight RXST Stock Holding History

MetLife Investment Management’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Buy	21,847 +292	+1%	+$1.76K	﹤0.01%	2755
2026 Q1	$133K	Sell	21,555 -204	-0.9%	-$1.69K	﹤0.01%	2413
2025 Q4	$227K	Hold	21,759	–	–	﹤0.01%	2209
2025 Q3	$196K	Hold	21,759	–	–	﹤0.01%	2329
2025 Q2	$283K	Hold	21,759	–	–	﹤0.01%	1991
2025 Q1	$549K	Sell	21,759 -195	-0.9%	-$5.79K	﹤0.01%	1685
2024 Q4	$755K	Buy	21,954 +1,429	+7%	+$64.4K	﹤0.01%	1567
2024 Q3	$1.01M	Buy	20,525 +790	+4%	+$40.5K	0.01%	1380
2024 Q2	$1.19M	Buy	19,735 +5,217	+36%	+$298K	0.01%	1257
2024 Q1	$749K	Hold	14,518	–	–	0.01%	1457
2023 Q4	$585K	Hold	14,518	–	–	﹤0.01%	1596
2023 Q3	$405K	Hold	14,518	–	–	﹤0.01%	1765
2023 Q2	$418K	Buy	14,518 +2,408	+20%	+$53.6K	﹤0.01%	1816
2023 Q1	$202K	Hold	12,110	–	–	﹤0.01%	2217
2022 Q4	$153K	Hold	12,110	–	–	﹤0.01%	2405
2022 Q3	$145K	Hold	12,110	–	–	﹤0.01%	2478
2022 Q2	$171K	Buy	+12,110	New	+$160K	﹤0.01%	2427

Other funds holding RXST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.66B AUM 39.91% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MetLife Investment Management's RXST Position: Q2 2026 in Review

MetLife Investment Management increased its RxSight (RXST) stake by 1.4% in Q2 2026, buying an estimated $1.76K and bringing the position to 21,847 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #2755.

MetLife Investment Management first reported a position in RXST in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.19M in Q2 2024. 152 funds tracked by Wall St. Rank hold RXST as of Q2 2026.

MetLife Investment Management held 21,847 shares of RxSight worth $105K as of Q2 2026.
MetLife Investment Management bought 292 RxSight shares in Q2 2026, an estimated $1.76K.
RxSight made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2755 holding.
MetLife Investment Management first reported a position in RxSight in Q2 2022 and has held it in 17 quarters since.
MetLife Investment Management's RxSight position peaked at $1.19M in Q2 2024.
152 funds tracked by Wall St. Rank held RxSight as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.